Sendai Isawa Family Katsuyama Sake Brewery: SAMURAI SAKE: Reviving a 300-Year-Old Recipe
16.1.2025 06:00:00 CET | Business Wire | Press release
“RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cru” New Release
Sendai Isawa Family Katsuyama Sake Brewery Co., Ltd.:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109261916/en/
Presented in a handcrafted Sendai Tansu (Photo: Business Wire)
A Legacy of Supporting Sendai's Samurai Warlord, Date Masamune
Sendai Isawa Family Katsuyama Sake Brewery Co., Ltd., which has a history of over 330 years as the official sake brewer for the Sendai Domain founded by the feudal lord Date Masamune, released RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cruon December, 2024.
This sake, crafted by unraveling a recipe from 300 years ago, achieves a quality that extracts "twice the umami components of rice" through Katsuyama Brewery's unique centrifugal pressing method. Then, through 12 years of ice aging at minus 5 degrees Celsius, this sake has reached a level of maturity brought about by time.
Shaped by Date Masamune's legacy as a samurai leader and cultural patron, Sendai embodies his vision through international exchange and crafts like Sendai Tansu. Katsuyama Sake Brewery, the Date family's official brewery for over 300 years, honors this heritage while crafting globally renowned sake.
Winner of Prestigious Sake Competitions Worldwide!
Katsuyama Sake Brewery has earned numerous accolades. Junmai Ginjo "Ken" topped the SAKE COMPETITION in 2015 and 2016 and was Champion Sake at the 2019 London IWC. That year, Junmai Daiginjo "Den" won the President Sake title at France's KURA MASTER. Flagship Junmai Daiginjo "Akatsuki" scored 95 points from Robert Parker's Wine Advocate in 2016, ranked first among 800 new sakes, and placed second in the 2024 SAKE COMPETITION Super Premium category.
An Uniquely Exceptional Sake, Reviving a 300-Year-Old Recipe
The theme "Ryoan" honors Heizaemon Isawa, the sixth-generation owner of Katsuyama Sake Brewery, who played a key role in Sendai's growth. His restoration of Zuihō-ji, the Date family's ancestral temple, preserved traditional culture. Inspired by the legacies of Masamune and Heizaemon, RYOAN LEGEND 2012 Junmai Daiginjo embodies Sendai's history, Samurai’s pride, and innovation.
Inspired by Edo-period (1603-1868) sake recipes, this sake combines tradition and innovation. Using historical methods, it amplifies umami, unlocking rice's potential for a rich, smooth finish. Made from 2012 Yamada Nishiki Special A rice, grown near Mount Izumigatake with silica-rich water, it reflects Katsuyama’s unique terroir. With centrifugal extraction and 12 years of cold aging, it achieves a perfect balance of depth, umami, and crispness.
Presented in a handcrafted Sendai Tansu, this limited release of 50 sets offers an unparalleled experience of premium rice’s sake.
RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cru |
Ingredients: Rice (domestic), Rice Koji (domestic rice) |
Polishing Ratio: 35% |
Rice Variety: 100% Yamada Nishiki |
Alcohol Content: 16% |
Volume: 720ml |
Storage: Refrigerated (room temperature during transport is acceptable) |
Brewmaster: Mitsuaki Goto |
Recommended Serving Temperature: 8–14°C |
Price: ¥1,000,000 (excluding tax) |
Sales: Limited to 50 bottles |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109261916/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom